Shot in the dark - look at OMRICatalyst helped get OMRI (nasdaq) on the map. OMRI specializes in biopharmaceutical and immunotherapy products derived from human plasma. It could be possible Catalyst has, in fact, found a situation that would be of importance to OMRI. OMRI is well established now and probably needs additional facilities? Maybe they could use the patents but it isn't that important to them so they are not being treated with priority?